Tecan appoints Mukta Acharya Head of the Life Sciences Business division
Männedorf, Switzerland, June 24, 2024 - The Tecan Group (SIX Swiss Exchange:
TECN) announced today that Mukta Acharya, currently serving as President, Tecan
Americas, has been appointed the new Head of the Life Sciences Business division
and a member of the Management Board of the Tecan Group. She is expected to
assume her new position on August 1, 2024.
Dr. Klaus Lun, Head of the Life Sciences Business since 2017 and a member of the
Management Board since 2013, has decided to leave the company to pursue other
career opportunities.
Dr. Achim von Leoprechting commented: «We are very pleased to have Mukta Acharya
take on this important role. It is a testament to the strength of our management
team that we can promote from within for such a key position. Mukta has had
significant success in growing our US business and building a strong
organization. She brings a wealth of industry expertise, having worked in senior
positions at market-leading organizations in the life sciences and broader
healthcare markets. With her impressive track record and her dynamic leadership
style, we are confident that she will continue to drive growth and further
enhance our competitive edge.»
Mukta Acharya joined Tecan in July 2022 as President, Tecan Americas, where she
was responsible for the successful financial and market performance of the Life
Sciences Business division in the company's largest sales region.
Mukta Acharya joined Tecan from Thermo Fisher Scientific (NYSE: TMO), where she
most recently served as Vice President and General Manager of the Single-use
Flexible Solutions business. In this role, she drove the strategic growth of the
global business, which spanned multiple manufacturing sites and thousands of
employees worldwide. She also oversaw product management, marketing,
engineering, and business development across the organization's various business
units.
From 2010 to 2018, Mukta Acharya held leadership positions at CVS Health (NYSE:
CVS), most recently as Director, Enterprise Product Innovation & Management.
Prior to that, she worked in management consulting.
She has a bachelor's degree in Mechanical Engineering from India and a master's
degree in Engineering Management from Dartmouth College in the United States.
Under Klaus Lun's leadership, the Life Sciences Business division achieved
significant growth and successfully navigated the challenges of the Covid-19
pandemic. Tecan's Board of Directors and CEO would like to express their sincere
gratitude to Klaus Lun for his strong engagement and important service of
developing Tecan's Life Sciences Business and wish him all the best for the
future.
About Tecan
Tecan (www.tecan.com) improves people's lives and health by empowering customers
to scale healthcare innovation globally from life science to the clinic. Tecan is a pioneer and global leader in laboratory automation. As an original equipment manufacturer (OEM), Tecan is also a leader in developing and manufacturing OEM instruments, components and medical devices that are then distributed by partner companies. Founded in Switzerland in 1980, the company has more than 3,500 employees, with manufacturing, research and development sites in Europe, North America and Asia, and maintains a sales and service network in over 70 countries. In 2023, Tecan generated sales of CHF 1,074
million (USD 1,194 million; EUR 1,108 million). Registered shares of Tecan Group
are traded on the SIX Swiss Exchange (TECN; ISIN CH0012100191).
For further information:
Tecan Group
Martin Brändle
Senior Vice President, Corporate Communications & IR
Tel. +41 (0) 44 922 84 30
Fax +41 (0) 44 922 88 89
investor@tecan.com
www.tecan.com
Â